Sugi Predict

Sugi Predict / Compounds / SCHEMBL519974

SCHEMBL519974

SCHEMBL519974

CCOC(=O)c1ccccc1B(O)O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.71
▸ HSD17B10 Q99714 4/20 0.61
▸ ALDH1A1 P00352 3/20 0.61
▸ CDC25B P30305 2/20 0.51
▸ MAPT P10636 3/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ USP2 O75604 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ MAPK10 P53779 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ PTK2B Q14289 1/20 0.51
▸ NCOA1 Q15788 1/20 0.51
▸ NCOA3 Q9Y6Q9 1/20 0.51
▸ KDM4E B2RXH2 4/20 0.49
▸ MAOB P27338 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29710304 1.00 TSHR (0.71) TSHRHSD17B10ALDH1A1CDC25BMAPT
SCHEMBL5110143 0.90 TSHR (0.62) TSHRHSD17B10ALDH1A1CDC25BMAPT
SCHEMBL28786302 0.86 TSHR (0.61) TSHRHSD17B10ALDH1A1CDC25BMAPT
Diethyl Phthalate SCHEMBL29404255 0.84 TSHR (1.00) TSHRHSD17B10ALDH1A1CDC25BMAPT
Diethyl Phthalate SCHEMBL5306972 0.84 TSHR (1.00) TSHRHSD17B10ALDH1A1CDC25BMAPT
Diethyl Phthalate SCHEMBL22296 0.84 TSHR (1.00) TSHRHSD17B10ALDH1A1CDC25BMAPT
SCHEMBL2472995 0.83 TSHR (0.58) TSHRHSD17B10ALDH1A1CDC25BMAPT
SCHEMBL29952536 0.83 TSHR (0.58) TSHRHSD17B10ALDH1A1CDC25BMAPT
SCHEMBL2359225 0.83 TSHR (0.75) TSHRHSD17B10ALDH1A1CYP1A2CYP3A4
SCHEMBL29617021 0.82 TSHR (0.80) TSHRHSD17B10ALDH1A1CDC25BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115433364-A Hydrogen bond organic molecular framework material HOF-NBDA and preparation method and application thereof 中国科学院福建物质结构研究所 2022-12-06 — — CN claimed
US-9162999-B2 Catalytic conversion of cellulose to fuels and chemicals using boronic acids WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2015-10-20 — — US claimed
EP-2059227-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY Aeris Therapeutics, Inc. (US) 2009-05-20 — — EP claimed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 — — WO claimed
CN-117659086-B Axis chiral biaryl diphosphine ligand, preparation method and application thereof 中国科学技术大学 2026-05-15 — — CN disclosed
US-12262634-B2 Organic electroluminescence device and novel compound IDEMITSU KOSAN CO., LTD. (JP) 2025-03-25 — — US disclosed
EP-3723149-B1 ORGANIC ELECTROLUMINESCENT ELEMENT AND NOVEL COMPOUND IDEMITSU KOSAN CO (JP) 2025-03-12 — — EP disclosed
CN-119431297-A Condensed ring compound and application thereof 郑州同源康医药有限公司 2025-02-14 — — CN disclosed
WO-2025026442-A1 FUSED RING COMPOUND AND USE THEREOF 郑州同源康医药有限公司 2025-02-06 — — WO disclosed
WO-2024208292-A1 UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITOR, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 江苏亚虹医药科技股份有限公司 2024-10-10 — — WO disclosed
CN-115259240-B Cobalt-free positive electrode material, preparation method thereof and lithium ion battery 蜂巢能源科技股份有限公司 2024-04-23 — — CN disclosed
CN-117659086-A Axis chiral biaryl diphosphine ligand, preparation method and application thereof 中国科学技术大学 2024-03-08 — — CN disclosed
WO-2004035576-A2 PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2004-04-29 — — WO disclosed
EP-1216238-B1 CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK FROSST CANADA INC (CA) 2004-02-18 — — EP disclosed
US-20030225110-A1 Tetrahydroquinoline derivatives as antithrombotic agents BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-12-04 — — US disclosed
WO-2003015715-A2 TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-02-27 — — WO disclosed
US-20020137746-A1 Method of treating or preventing urinary incontinence using prostanoid EP1 receptor antagonists CARL FRANCOIS JOSEPH (CA) 2002-09-26 — — US disclosed
EP-1216238-A2 CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT Merck Frosst Canada & Co. (CA) 2002-06-26 — — EP disclosed
US-6369084-B1 PROSTAGLANDIN MEDIATED DISEASES MERCK FROSST CANADA & CO. (CA) 2002-04-09 — — US disclosed
WO-2001019814-A2 CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK FROSST CANADA & CO. (CA) 2001-03-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225110-A1 Tetrahydroquinoline derivatives as antithrombotic agents TFPI, TFPI2, SERPINC1 TSHR 2853/4885HSD17B10 2007/4885ALDH1A1 2602/4885
US-12262634-B2 Organic electroluminescence device and novel compound PIEZO1, TMEM109, OXA1L TSHR 4540/4885HSD17B10 1182/4885ALDH1A1 17/4885
US-20020137746-A1 Method of treating or preventing urinary incontinence using prostanoid EP1 receptor antagonists PTGER1, PTGIR, PTGS1 TSHR 2452/4885HSD17B10 715/4885ALDH1A1 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.